Hydroxychloroquine or Hydroxychloroquine sulfate is an anti-malarial drug commonly referred by its brand name Plaquenil. Hydroxychloroquine was first approved for medical use in the United States in 1955. This is an oral pill that also helps in treating patients suffering from Malaria and also at times for lupus and rheumatoid arthritis. It is on the WHO’s list of essential medicines, as the safest and most effective medicines available. Presently, this drug is being studied for the treatment of coronavirus.
The Food and Drug Administration of the US had approved a Swiss pharma- NOVN:VX that will be proceeding towards Phase III clinical trial with around 440 covid patients, that will be given hydroxychloroquine for the treatment who are hospitalized.
The old generic medicine got FDA emergency use authorization for its unapproved use against coronavirus, where there has been no scientific proof that it will work. The new approval from the FDA for the usage of hydroxychloroquine has brought mixed reactions. Comments are made on the drug that can be potential and untested. This is now bringing a shortage of the drug and danger to patients with lupus and rheumatoid arthritis for being unable to access the treatment. Presently, there is no approved medicines to treat COVID-19.https://www.healio.com/rheumatology/practice-management/news/online/%7Bb698e9fe-1f57-4ab0-bfe0-8ca6239d7e8e%7D/fdas-hydroxychloroquine-emergency-use-order-for-covid-19-draws-mixed-reactions)
Hydroxychloroquine sulfate has not yet been approved to treat COVID-19 but it is being experimentally used to treat a certain group of COVID-19 patients, including the severely diseased. The drug is given to try and stop the spread of the covid19 virus inside the body. Hydroxychloroquinesulfateis totally experimental and researchers have no clue whether it will work for coronavirus or not. It has not been approved by the FDA for treatment of coronavirus, but emergency use has been provided to adults and adolescents who weigh 50kg or more and are hospitalized with COVID-19.
The United States received 29 million doses of Hydroxychloroquine from India, the largest producer of the drug. President Donald Trump praised the PM for allowing the export of the anti-malarial drug and help treat the increasing number of COVID patients.
The CEO of Novartis, Vas Narasimhan had previously told that hydroxychloroquine was praised by US President Donald Trump as a ‘game changer’and is one of the biggest hopes to treat the patient with coronavirus. However, there are exceptions that this promoting has blocked the side effects of the drug-like loss of vision and heart problems that correlate to the use of the drug.
Novartis, Roche (ROG.S) and Gilead Sciences(GILD.O) companies are in the process of testing older medicines that were developed to treat other diseases and could help tackle the viral epidemic in the U.S.
The University of Washington, University of Minnesota and the National Institutes of Health in the United States are performing several studies on hydroxychloroquine. Novartis’s Sandoz generics unit promised to donate 130 million doses of the medicine for use to coronavirus. Sanofi also mentioned that it would be donating 100 million doses of the drug hydroxychloroquine to 50 countries.
The confirmed cases in the United States have raised to 770,564 and 41,114 deaths, treatment towards coronavirus is essential. To avoid community spread and getting tested to prevent severe symptoms. Locate your COVID-19 testing centers nearby you with the help of https://www.carenearby.com